00:21 , Jun 23, 2017 |  BC Extra  |  Clinical News

Paper describes Affiris' PCSK9 vaccine's efficacy

In a paper published in the...
23:30 , Jun 22, 2017 |  BC Week In Review  |  Clinical News

Affiris' Affitope PD03A well tolerated in Phase I to treat early PD

Affiris AG (Vienna, Austria) reported top-line data from a single-blind, placebo-controlled, Austrian Phase I AFF011 trial in 36 patients with early Parkinson’s disease (PD) showing that 15 and 75 µg doses of subcutaneous Affitope PD03A...
07:00 , Aug 26, 2016 |  BC Extra  |  Company News

Management tracks

Vaccine developer Vaxxilon AG (Reinach, Switzerland) named Arne von Bonin CSO. He was CSO at Affiris AG (Vienna, Austria). Shanghai Pharmaceuticals Holding Co. Ltd. (HKSE:02607; Shanghai:601607) said Jie Zhou resigned as its chairman. The company's...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Affiris completes venture financing

Affiris AG , Vienna, Austria   Business: Neurology, Cardiovascular, Endocrine/Metabolic   Date completed: 2016-06-23   Type: Venture financing   Raised: EUR10 million ($11.3 million)   Investors: Santo Holding; MIG Funds; FCPG Affi  ...
00:19 , Jun 24, 2016 |  BC Extra  |  Financial News

Affiris raises EUR 10M

Affiris AG (Vienna, Austria) said it raised EUR 10 million ($11.3 million) from FCPB Affi GmbH and existing investors Santo Holding GmbH and MIG Funds. Affiris expects Phase I data in 1Q17 for AT04A and...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Financial News

Affiris completes venture financing

Affiris AG , Vienna, Austria   Business: Neurology, Cardiovascular, Endocrine/Metabolic   Date completed: 2015-06-16   Type: Venture financing   Raised: EUR10 million ($11.2 million)   Investors: Santo Holding; MIG Funds  ...
01:57 , Mar 21, 2015 |  BC Extra  |  Clinical News

Prothena soars on Phase I Parkinson's data

Prothena Corp. plc (NASDAQ:PRTA) rose $9.43 (32%) to $38.66 on Friday after it said Parkinson's disease (PD) candidate PRX002 reduced free serum alpha synuclein ( SNCA ) levels by up to 96% in a Phase...
07:00 , Mar 19, 2015 |  BC Innovations  |  Targets & Mechanisms

Untangling α-synuclein

The Michael J. Fox Foundation for Parkinson's Research (MJFF) wants to settle the question of what form of α-synuclein drives the pathology of Parkinson's disease. To make sure the data hold up in different labs...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

Affitope PD03A: Phase I started

Affiris and the SYMPATH consortium began the single-blind, placebo-controlled, Austrian Phase I AFF011 trial to evaluate 4 injections of 15 and 75 µg subcutaneous Affitope PD03A plus an adjuvant every 4 weeks in about 36...
08:00 , Nov 6, 2014 |  BC Innovations  |  Tools & Techniques

AD goes 3D

A 3D cell-based model that encapsulates the two hallmark features of Alzheimer's disease-neurofibrillary tangles and b-amyloid plaques-has been created by a team at Massachusetts General Hospital to help screen compounds for the disease. 1 Although...